ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 178 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,312 | -58.3% | 197,723 | -44.6% | 0.00% | -62.5% |
| Q2 2023 | $12,726 | +58.6% | 356,881 | +12.9% | 0.01% | +100.0% |
| Q1 2023 | $8,026 | -41.7% | 315,982 | -6.8% | 0.00% | -33.3% |
| Q4 2022 | $13,757 | -99.9% | 339,181 | +13.7% | 0.01% | -45.5% |
| Q3 2022 | $9,859,000 | +17.8% | 298,297 | +25.5% | 0.01% | +120.0% |
| Q2 2022 | $8,372,000 | +24.8% | 237,760 | +63.0% | 0.01% | 0.0% |
| Q1 2022 | $6,710,000 | -81.1% | 145,909 | -72.7% | 0.01% | -28.6% |
| Q4 2021 | $35,448,000 | +161.2% | 534,644 | +145.9% | 0.01% | +16.7% |
| Q3 2021 | $13,571,000 | -20.9% | 217,384 | +5.0% | 0.01% | -25.0% |
| Q2 2021 | $17,148,000 | +15.2% | 207,069 | -7.7% | 0.01% | 0.0% |
| Q1 2021 | $14,883,000 | +18.0% | 224,435 | +36.5% | 0.01% | +14.3% |
| Q4 2020 | $12,615,000 | +47.2% | 164,396 | -17.4% | 0.01% | +40.0% |
| Q3 2020 | $8,568,000 | +1.5% | 198,963 | +1.8% | 0.01% | -28.6% |
| Q2 2020 | $8,445,000 | +57.8% | 195,522 | +5.1% | 0.01% | +75.0% |
| Q1 2020 | $5,351,000 | -40.9% | 185,948 | +30.2% | 0.00% | -20.0% |
| Q4 2019 | $9,058,000 | +190.7% | 142,813 | +29.2% | 0.01% | +150.0% |
| Q3 2019 | $3,116,000 | -0.5% | 110,547 | -6.4% | 0.00% | 0.0% |
| Q2 2019 | $3,131,000 | +145.2% | 118,130 | +69.9% | 0.00% | +100.0% |
| Q1 2019 | $1,277,000 | +734.6% | 69,534 | +462.3% | 0.00% | – |
| Q4 2018 | $153,000 | -85.6% | 12,365 | -77.7% | 0.00% | -100.0% |
| Q3 2018 | $1,062,000 | +21.6% | 55,350 | -13.7% | 0.00% | 0.0% |
| Q2 2018 | $873,000 | -6.9% | 64,152 | -50.7% | 0.00% | 0.0% |
| Q1 2018 | $938,000 | +67.8% | 130,172 | -14.2% | 0.00% | – |
| Q4 2017 | $559,000 | +117.5% | 151,773 | +155.2% | 0.00% | – |
| Q3 2017 | $257,000 | +3.2% | 59,465 | -61.5% | 0.00% | – |
| Q2 2017 | $249,000 | +79.1% | 154,298 | +106.6% | 0.00% | – |
| Q1 2017 | $139,000 | +124.2% | 74,692 | +83.0% | 0.00% | – |
| Q4 2016 | $62,000 | -78.8% | 40,805 | +2.6% | 0.00% | – |
| Q3 2016 | $293,000 | +202.1% | 39,772 | +114.3% | 0.00% | – |
| Q2 2016 | $97,000 | – | 18,560 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 908,474 | $24,410,696 | 22.12% |
| Western Financial Corp/CA | 820,239 | $22,039,822 | 16.16% |
| JOHNSON & JOHNSON | 247,598 | $6,652,958 | 2.45% |
| WEALTH EFFECTS LLC | 164,750 | $4,426,835 | 2.19% |
| M28 Capital Management LP | 67,400 | $1,811,038 | 2.08% |
| Privium Fund Management B.V. | 259,036 | $6,960,298 | 2.07% |
| Evolutionary Tree Capital Management, LLC | 51,266 | $1,377,517 | 1.78% |
| Avidity Partners Management LP | 1,063,897 | $28,586,912 | 1.15% |
| SECTORAL ASSET MANAGEMENT INC | 157,552 | $4,233,422 | 0.82% |
| Vivo Capital, LLC | 137,411 | $3,692,234 | 0.40% |